The light and dark side of bisphosphonates

Eijiro Jimi, Masamichi Takami, Toru Hiraga, Ichiro Nakamura, Masahiro Urade, Yoichi Miyamoto

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)

Abstract

Bisphosphonates are stable compounds of pyrophosphoric acid that inhibit hydroxyapatite formation. This class of chemical was first investigated in the 1960s for use in the treatment of disorders of bone metabolism. Bisphosphonates have been developed for clinical use since then, and, currently, the third, nitrogen-containing, generation of bisphosphonates is widely used for the treatment of various bone diseases, including osteoporosis and bone metastases in cancer. However, despite the therapeutic benefits, the emergence of bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a growing and significant problem in a subset of patients receiving these drugs. In this review, we introduce the benefits and risks of bisphosphonates,"the light and dark side"so to speak, to facilitate a full understanding of these compounds.

Original languageEnglish
Pages (from-to)177-187
Number of pages11
Journaljournal of oral biosciences
Volume51
Issue number4
DOIs
Publication statusPublished - Nov 2009
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Dentistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'The light and dark side of bisphosphonates'. Together they form a unique fingerprint.

Cite this